Eli Lilly and Company (NYSE:LLY) finished Thursday with an addition of $2.05 to close at $550.05, an upside of 0.37 percent. An average of 1,714,089 shares of common stock have been traded in the last five days. There was a gain of $4.28 in the past week, and it reached a new high 45 times over the past 12 months. The last 20 days have seen an average of 3,176,762 shares traded, while the 50-day average volume stands at 2,858,741.
LLY stock has increased by 20.89% in the last month. The company shares reached their 1-month lowest point of $446.56 on 07/26/23. With the stock rallying to its 52-week high on 08/23/23, shares of the company touched a low of $296.32 and a high of $557.40 in 52 weeks. It has reached a new high 33 times so far this year and achieved 50.35% or $184.87 in price. In spite of this, the price is down -1.32% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
LLY stock investors should be aware that Eli Lilly and Company (LLY) stock had its last reported insider trading activity 2 days ago on Aug 23. In this transaction, the insider spent $726,284. SVP, Finance, & CAO, Zakrowski Donald A, disposed of 600 shares at a price of $546.51 on Aug 21. The insider now owns more than $327,906 worth of shares. Prior to that, 10% Owner LILLY ENDOWMENT INC went on to Sale 50,222 shares at $543.72 each on Aug 15. An amount of $27,306,747 was transacted.
Valuation Metrics
Eli Lilly and Company (LLY) has a trailing price-to-earnings (P/E) ratio of 76.42. The stock’s beta is 0.28. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 17.41, the price-to-book (PB) ratio at 44.71, and the price-to-cash flow ratio at 159.99.
The company has a payout ratio of 58.73%. The company’s most recent quarterly dividend payment was $1.13 a share, without any change from last year. Its latest increase dividend $0.15 reported on Monday December 12 2022.
Financial Health
The quick ratio of Eli Lilly and Company for the three months ended June 29 was 0.90, and the current ratio was 1.10, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.64 and a total debt to equity ratio of 1.70 for the quarter ending June 29. Eli Lilly and Company’s EBITDA margin for the year ending June 29 is 34.35%. Its gross profit as reported stood at $21.91 billion compared to revenue of $28.54 billion.
Earnings Surprise
For the three-month period that ended June 29, Eli Lilly and Company had $18.16 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.76 billion in the quarter, while revenues of $1.34 billion were grew 45.98%. The analyst consensus anticipated Eli Lilly and Company’s latest quarter earnings to come in at $1.98 per share, but it turned out to be $2.11, a 6.60% surprise. For the quarter, EBITDA amounted to $2.49 billion. Shareholders own equity worth $949.29 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Eli Lilly and Company (LLY) price momentum. RSI 9-day as of the close on 24 August was 74.46%, suggesting the stock is Overbought, with historical volatility in this time frame at 15.83%.
As of today, LLY’s price is $551.16 +0.78% or $4.28 from its 5-day moving average. LLY is currently trading +20.12% higher than its 20-day SMA and +57.01% higher than its 100-day SMA. However, the stock’s current price level is +23.00% above the SMA50 and +50.85% above the SMA200.
The stochastic %K and %D were 91.77% and 94.61%, respectively, and the average true range (ATR) was 11.23. With the 14-day stochastic at 87.77% and the average true range at 11.45, the RSI (14) stands at 74.28%. The stock has reached 2.61 on the 9-day MACD Oscillator while the 14-day reading was at 10.11.
Analyst Ratings
Jefferies upgraded Eli Lilly and Company (NYSE: LLY) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold.
